How close are we to having an anti‑pepsin medication for laryngopharyngeal reflux (LPR)?

Anti-Pepsin Medication for LPR: Current Status

We are in early-stage clinical development of anti-pepsin therapy for LPR, with inhaled fosamprenavir showing promise in preclinical studies, but no FDA-approved anti-pepsin medication currently exists or is imminently available for clinical use. 1

Current State of Development

Fosamprenavir (FOS) - The Leading Candidate

The most advanced anti-pepsin medication under investigation is inhaled fosamprenavir, an HIV protease inhibitor repurposed to inhibit pepsin activity in the laryngopharynx. Here's where we stand:

• Preclinical safety established: A 4-week pre-GLP toxicology study in an LPR mouse model demonstrated no significant histologic lesions, cytokine elevation, or cardiotoxicity markers with aerosolized fosamprenavir 1

• Mechanism validated: Fosamprenavir prevents pepsin-mediated damage in animal models at lower doses when inhaled compared to oral administration 1

• Delivery system optimized: Computational fluid dynamics modeling has identified the optimal particle size (8.1-11.5 μm aerodynamic diameter) for laryngopharyngeal deposition via dry powder inhaler 1

• Current timeline: A formal GLP (Good Laboratory Practice) assessment is underway to support a Phase I clinical trial 1

The Reality Check

We are likely 5-10+ years away from an FDA-approved anti-pepsin medication, assuming the following hurdles are cleared:

1. Completion of formal GLP toxicology studies (ongoing)
2. Phase I safety trials in humans (next step)
3. Phase II dose-finding and efficacy studies
4. Phase III randomized controlled trials
5. FDA review and approval process

Why This Matters: The Pepsin Problem

Recent research has clarified pepsin's central role in LPR pathophysiology:

• Pepsin drives inflammation independently: Pepsin activates the ROS/NLRP3/IL-1β inflammatory pathway, causing direct mucosal injury even in weakly acidic environments 2

• Weak acid + pepsin = damage: Animal studies confirm that pepsin combined with weak acid (pH 4-7) causes significant laryngeal mucosal barrier injury, downregulates E-cadherin, and widens intercellular spaces 3

• Current therapies miss the target: PPIs reduce acid but don't eliminate pepsin, which remains active at pH up to 6.5 and can cause damage even when acid is suppressed 4

Current Treatment Landscape (What We Have Now)

Based on the 2023 AGA guidelines, here's the algorithmic approach while awaiting anti-pepsin therapy 4:

First-Line Approach

• Twice-daily PPI for 8-12 weeks in patients with documented reflux or concomitant esophageal symptoms 4
• Diet and lifestyle modifications: Recent 2025 data shows 88.6% symptom improvement with low-fat, high-protein, low-sugar diet alone 5

Second-Line Options

• Alginate-containing antacids: Forms a physical barrier, though placebo-controlled trials show equivocal results 4
• Upper esophageal sphincter assist device (UESAD): A 2025 RCT showed significant symptom improvement and pepsin reduction with external cricoid pressure, even at lower pressures (4-11 mmHg), suggesting this is a safe and effective option 6

Important Caveats

PPI failure is common in LPR for three reasons 4:

1. True PPI failure with ongoing acid reflux
2. Adequate acid suppression but ongoing non-acid/weakly acidic reflux (where pepsin remains active)
3. Non-GERD factors contributing to symptoms

Salivary pepsin testing has limited clinical utility despite conceptual appeal—poor concordance with esophageal monitoring and overlap with healthy controls limits enthusiasm 4

Bottom Line for Clinical Practice

Until anti-pepsin medications become available:

1. Optimize acid suppression: Twice-daily PPI for 8-12 weeks in appropriate patients
2. Emphasize dietary intervention: The 2025 prospective study showing 88.6% response to diet alone is compelling 5
3. Consider UESAD: The 2025 RCT data supports this as a safe, non-invasive option with significant pepsin reduction 6
4. Manage expectations: Explain to patients that current therapies target acid but not pepsin, which may explain partial responses
5. Monitor clinical trials: Fosamprenavir represents the first targeted anti-pepsin therapy, but clinical availability is years away

The field recognizes pepsin as the key therapeutic target, but translating this knowledge into approved medications requires completing the full drug development pipeline—a process we're only beginning 1, 2.